Cardio Diagnostics Hldgs Azioni (NASDAQ: CDIO)

Ultime notizie per Cardio Diagnostics Hldgs (NASDAQ:CDIO) Azioni

Cardio Diagnostics Hldgs

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc. - Warrant

Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/05/b45205997/lattice-semiconductor-reports-first-quarter-2025-results">details from the report. </a>
The Details: Lattice Semiconductor reported quarterly earnings of 22 cents per share, in line with the analyst consensus estimate. Quarterly revenue came in at $120.15 million, which beat the analyst consensus estimate of $120.13 million, but is down from revenue of $140.81 million from the same period last year.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
&#8220;The first quarter of 2025 developed as expected, with sequential revenue growth, a record level of design wins, and a further expansion of our operating margins. Revenue and design win growth are being led by new applications, notably in generative AI in the datacenter, robotics in industrial, in-cabin and ADAS in automotive, AR/VR in consumer, security, including post-quantum cryptography, and far edge AI for lower power applications,&#8221; Ford Tamer, CEO of Lattice, said. 
While we are encouraged by our progress, we are monitoring the market environment, along with the broader industry, as it could have an impact on our outlook,&#8221; Tamer added. 
Outlook:&nbsp;Lattice Semiconductor sees second-quarter adjusted earnings of between 22 cents and 26 cents per share, versus the 24 cent estimate, and revenue in a range of&nbsp;$118.5 million to $128.5 million, versus the&nbsp;$123.61 million&nbsp;analyst estimate.
LSCC Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Lattice Semiconductor stock was down 2.78% after hours at $51 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Earnings

News

After-Hours Center

Movers

Tech

LSCC

Lattice Semiconductor Shares Slide After Q1 Results: Details

Dover Corporation (NYSE:&nbsp;DOV) today announced that it has entered into a definitive agreement to acquire SIKORA AG ("SIKORA" or the "Company") for €550 million in cash, subject to customary adjustments. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals. Following the closing of the transaction, SIKORA will become part of Dover's MAAG operating unit within Dover's Pumps &amp; Process Solutions segment.

Dover To Acquire SIKORA For €550 Million In Cash

The mission will launch a single synthetic aperture radar (SAR) imaging satellite called QPS-SAR-10 (nicknamed "WADATSUMI-I" for the Japanese god of the sea) to a 575km circular Earth orbit, from where the satellite will join the rest of the iQPS constellation in providing high resolution images and Earth monitoring services globally.

RKLB

Rocket Lab Schedules Next Mission For Institute For Q-shu Pioneers Of Space; Launch Window Opens May 17, 2025

Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) .Lowers FY 2025 Production Guidance to 15,000–17,000 Boe/Day from Prior Range of 17,000–18,000

Guidance

Vitesse Energy Lowers FY 2025 Production Guidance to 15,000–17,000 Boe/Day from Prior Range of 17,000–18,000

Earnings Beats

CORRECTION: Fabrinet Q3 Adj. EPS $2.52 Beats $2.49 Estimate, Sales $871.80M Beat $856.62M Estimate

Management

Fold Holdings Appoints Matthew McManus As COO, Effective 21, 2025

Teradata Appoints John Ederer As CFO

RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) has outperformed the market over the past 5 years by 2.97% on an annualized basis producing an average annual return of 16.99%. Currently, RTX has a market capitalization of $171.67 billion. 
Buying $100 In RTX: If an investor had bought $100 of RTX stock 5 years ago, it would be worth $225.56 today based on a price of $128.50 for RTX at the time of writing.
<h3>RTX's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746477912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>), the leading provider of building materials solutions, is pleased to announce that it has completed the latest phase of its share buyback program, returning a further $0.3 billion of cash to shareholders.
Between February 27, 2025 and May 2, 2025, 3.3 million ordinary shares listed on the New York Stock Exchange were repurchased. This brings total cash returned to shareholders under our ongoing share buyback program to $8.8 billion since its commencement in May 2018.
CRH today also announces that it has entered into an arrangement with BNP Paribas Securities Corp. ("BNPP") to repurchase ordinary shares listed on the New York Stock Exchange on CRH's behalf for an aggregate maximum consideration of up to $0.3 billion (the "Buyback"). The Buyback will commence on May 6, 2025, and will end no later than August 5, 2025.
BNPP will conduct the Buyback on CRH's behalf and will make trading decisions under the Buyback independently of CRH in accordance with certain pre-set parameters. The maximum number of ordinary shares which may be acquired pursuant to the Buyback is 40,000,000. The purpose of the Buyback is to reduce the share capital of CRH.
The Buyback will be conducted within the parameters prescribed by (i) Rule 10b5-1 and Rule 10b-18 under the U.S. Securities Exchange Act of 1934, as amended and (ii) the EU Market Abuse Regulation (596/2014) and Commission Delegated Regulation (EU) 2016/1052 as such legislation forms part of the law in the United Kingdom ("UK") pursuant to the EU (Withdrawal) Act 2018 (as may be amended and/or supplemented from time to time). No repurchases will be made outside of the United States. The repurchased ordinary shares will be cancelled.

Buybacks

CRH Announces That It Has Completed Latest Phase Of Its Share Buyback Program Of $0.3B Of Cash To Shareholders

Builders FirstSource, Inc. (NYSE:<a href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) ("Builders FirstSource" or the "Company") today announced that it has priced an offering of $750 million aggregate principal amount of 6.750% unsecured Senior Notes due 2035 (the "Notes"), which represents a $250 million increase in the previously announced size of the offering. The price to investors will be 100.000% of the principal amount of the Notes.
The offering of the Notes is expected to close on May 8, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to repay indebtedness outstanding under its senior secured ABL facility.

Offerings

BLDR

Builders FirstSource Prices Offering Of $750M Of Senior Notes Due 2035

AROC

Archrock Sees FY25 Contract Operations Revenue $1.260M-$1.290M

Gibson Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GEI#TSX">GEI</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.25 by 20 percent. This is a 20 percent increase over earnings of $0.25 per share from the same period last year. The company reported $2.75 billion in sales this quarter. This is a 16.45 percent decrease over sales of $3.29 billion the same period last year.

TSX:GEI

Gibson Energy Q1 EPS $0.30 Beats $0.25 Estimate, Sales $2.75B Down From $3.29B YoY

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) reported financial results for the first quarter on Monday after the bell. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/b45206384/hims-hers-health-inc-reports-first-quarter-2025-financial-results">from the print</a>.
Q1 Earnings: Hims &amp; Hers Health reported first-quarter revenue of $586.01 million, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $538.2 million, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported first-quarter earnings of 20 cents per share, beating analyst estimates of 12 cents per share. 
Total revenue was up 111% on a year-over-year basis as subscribers grew to 2.4 million in the quarter, up 38% year-over-year. Gross margin came in at 73% in the first quarter. The company reported operating cash flow of $109.1 million and free cash flow of $50.1 million in the quarter.
&#8220;We&#8217;re starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes,&#8221; said&nbsp;Andrew Dudum, co-founder and CEO of Hims &amp; Hers Health.
&#8220;We&#8217;re building a platform that puts the individual at the center of every decision and others are taking notice. Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world-class providers.&#8221;
Guidance: Hims &amp; Hers Health guided for second-quarter revenue of $530 million to $550 million versus estimates of $564.56 million.
The company continues to expect full-year 2025 revenue to be in the range of $2.3 billion to $2.4 billion versus estimates of $2.32 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Hims &amp; Hers Health also provided a longer-term outlook, laying out expectations for at least $6.5 billion in annual revenue for full-year 2030, and adjusted EBITDA of at least $1.3 billion.
Hims &amp; Hers executives will hold a conference call at 5 p.m. ET to further discuss the company&#8217;s quarterly performance.
HIMS Price Action: <a href="http://benzinga.com/quote/hims" target="_blank" rel="noreferrer noopener">Hims &amp; Hers Health shares</a> were down 1.03% at $41.45 in Monday&#8217;s after-hours session at publication time, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45196511/hims-hers-appoints-ex-amazon-exec-ahead-of-q1-results">Hims &amp; Hers Appoints Ex-Amazon Exec Ahead Of Q1 Results</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/StormyDays">Lori Butcher</a>/Shutterstock.

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Q1 Earnings: Revenue Jumps 111%, Subscribers Up 38%, Q2 Guidance Falls Short Of Estimates, Shares Slide

Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) affirms FY2025 Adj EPS guidance from $9.60-$10.40 to $9.60-$10.40 vs $9.64 analyst estimate..

Regal Rexnord Affirms FY2025 Adj EPS Guidance of $9.60-$10.40 vs $9.64 Est

TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) sees Q2 sales of $392.000 million-$417.000 million vs $380.18 million analyst estimate.

TrueBlue Sees Q2 Sales $392.000M-$417.000M vs $380.18M Est

Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>), a global leader in electrical balance of system (EBOS) solutions for the energy transition market, announced today the execution of a Memorandum of Understanding (MOU) with UGT Renewables to collaborate on up to 12 gigawatts (GW) of global solar projects currently in UGT Renewables' development pipeline. This collaboration aims to bring innovative EBOS solutions to emerging markets, accelerating the energy transition and supporting sustainable development.
"We are always seeking best-in-class providers for our projects in order to deliver world-class American-led energy installations. We have a history with Shoals and are pleased to memorialize our intent to collaborate with Shoals regarding our existing 12GW of solar projects in the pipeline," Adam Cortese, CEO of UGT Renewables and Sun Africa said. "We have great confidence in Shoals' ability to design and deliver an EBOS solution that can operate efficiently in complex environments and is backed by an industry leading warranty. Shoals' BLA solution enables a superior levelized cost of electricity and requires less skilled labor than other solutions, which supports our need to accelerate reliable, low-cost electrification in emerging markets."
UGT Renewables partners with emerging markets and developing economies that are looking to diversify their energy matrix. In the Southern Provinces of Angola, Shoals and UGT Renewables' sister company, Sun Africa, have aligned to execute on the first two energy diversification projects with a combined capacity of 600 MW of Solar PV planned to begin deployment later this year.
These first projects, financed by EXIM Bank in the United States, are expected to break ground in 2025 and will play a crucial role in electrifying 60% of the Angolan population, providing clean water to over 1.1 million people.
"This collaboration with UGT Renewables and Sun Africa strengthens our position within international markets," Brandon Moss, CEO of Shoals stated. "We are looking forward to working together on these current projects and the opportunity to collaborate on future potential projects by supporting the deployment of our high-quality and innovative solutions."

Contracts

SHLS

Shoals Technologies Group, UGT Renewables And Sun Africa Announces Collaboration On Up To 12GW Of Solar Projects

Biotech

General

ARAY

Accuray Reports First SRS/SBRT Patient Treatments in Austria With the CyberKnife System

Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.38 by 10.53 percent. This is a 61.54 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $347.20 million which beat the analyst consensus estimate of $342.79 million by 1.29 percent. This is a 29.32 percent increase over sales of $268.49 million the same period last year.

Archrock Q1 Adj. EPS $0.42 Beats $0.38 Estimate, Sales $347.20M Beat $342.79M Estimate

Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $1.83 by 17.49 percent. This is a 7.5 percent increase over earnings of $2.00 per share from the same period last year. The company reported quarterly sales of $1.42 billion which beat the analyst consensus estimate of $1.37 billion by 3.63 percent. This is a 8.39 percent decrease over sales of $1.55 billion the same period last year.

Regal Rexnord Q1 Adj. EPS $2.15 Beats $1.83 Estimate, Sales $1.42B Beat $1.37B Estimate

Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures from the report. 
The Details: Ford Motor reported quarterly earnings of 14 cents per share, which beat the analyst consensus estimate of two cents, but is down from earnings of 49 cents per share from the prior year&#8217;s quarter. Quarterly revenue came in at $37.42 billion, which beat the analyst consensus estimate of $36.2 billion and is down from revenue of $39.89 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
For the first quarter, Ford reported: 
<ul>
<li>Ford Pro generated $1.3 billion in EBIT with a margin of 8.6% on $15.2 billion in revenue. </li>
<li>Ford Model e reported a first-quarter EBIT loss of $849 million. </li>
<li>Ford Blue reported $96 million in EBIT, down from a year ago due to expected volume decline and adverse exchange. Segment revenue declined 3% to $21 billion.</li>
<li>Ford Credit reported first-quarter earnings before taxes (EBT) of $580 million, up significantly compared to a year ago. </li>
</ul>
&#8220;We are strengthening our underlying business with significantly better quality and our third straight quarter of year-over-year cost improvement, excluding the impact of tariffs," said Ford CEO Jim Farley. 
"Ford Pro, our largest competitive advantage, is off to a strong start to the year, gaining market share in the most profitable U.S. and European customer segment,&#8221; Farley added.
Outlook: Ford suspended its financial guidance, including full-year adjusted EBIT and adjusted free cash flow, due to tariff-related uncertainty.
F Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Ford Motor stock was down 2.46% after hours at $9.92 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Ford Stock Hits The Brakes After Q1 Earnings, Suspends Guidance Due To 'Tariff-Related Uncertainty'

Press Releases

Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics' Heart Disease Tests

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

BIAF

CDIO

CSDX

INBS

SOBR

TRIB

ABVC BioPharma

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioVie

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Curis

CEL-SCI

Elevation Oncology

GlycoMimetics

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Longeveron

Leap Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

Nanoviricides

Ovid Therapeutics

Passage Bio

Portage Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Q32 Bio

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

X4 Pharmaceuticals

Benchmark

Northland Capital Markets

Screenshot 2024-09-16 at 6.26.11 PM

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics&#39; Heart Disease Tests

Screenshot 2024-05-23 at 10.15.30 PM

Interview

This Medtech Company Is Bringing &#34;Precision&#34; Medicine To Cardiovascular Diagnostics

Screenshot 2024-05-06 at 5.31.30 PM

New Study Shows Cardio Diagnostics&#39; (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Screenshot 2024-04-30 at 5.36.02 PM

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-04-23 at 6.35.19 PM

As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease

Screenshot 2024-04-11 at 5.31.26 PM

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Comments

Cardio Diagnostics Hldgs

Notizie

Ultime notizie per Cardio Diagnostics Hldgs (NASDAQ:CDIO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO